Aspirin not associated with decreased prostate cancer-associated mortality
the ONA take:
According to a recent study published in The Journal of Urology, researchers from Jewish General Hospital in Montreal, Quebec, Canada, have found that aspirin use does not decrease the risk of mortality associated with prostate cancer.
For the study, researchers followed a cohort of 11,779 men diagnosed with nonmetastatic prostate cancer between 1998 and 2009. Patients were followed until 2012 in order to assess associations between aspirin use and both prostate and all-cause mortality.
Results showed that a median follow-up of 5.4 years, aspirin use after cancer diagnosis was associated with increased risks of prostate cancer mortality (HR = 1.46; 95% CI: 1.26-1.50).
Researchers also found that the risk of prostate cancer-associated mortality was increased in patients who started using aspirin after they were were diagnosed with cancer (HR = 1.84; 95% CI: 1.59-2.12), whereas those who were using aspirin before diagnosis did not have an increased risk of cancer-associated mortality (HR = 0.97; 95% CI: 0.81-1.16.
The study showed similar risks for all cause-mortality and post- and pre-diagnostic aspirin use.
Aspirin use does not decrease the risk of mortality associated with prostate cancer.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|